

SECTOR: Specialty Pharmaceuticals

July 12, 2013

Lower prices for corn and soybean should drive livestock expansion for broilers and hogs in 2014. We hosted a conference call at 2:30p.m. ET yesterday with our WRG Agribusiness Analyst, Mark McMinimy, to discuss the July WASDE (World Agriculture Supply and Demand Estimates) data, which was released at noon ET yesterday. The July and August WASDE crop reports are closely watched for a current read on harvest prospects for 2013 crops and prices, which determine producers' decisions to expand herd sizes. Post the conference call, we are optimistic that livestock expansion for broilers and hogs will pick up in 2014 and cattle will pick up in 2015/2016. The possibility of broiler and hog expansion would be in line with our expectations. This is positive for Zoetis (ZTS, BUY, \$30.92), since ~ 66% of its sales are to the livestock industry. We are slightly less optimistic about the U.S. prospects for cattle expansion. The cattle slaughter statistics for female cows and calves do not yet point to a recovery, but we will not know for sure until the actual cattle report in January of 2014. A replay of the conference call will be available for five business days after the call at toll-free U.S./Canada: 1-800-964-3261; Int'l Toll: 402-220-0605.

- The July WASDE report suggests that the prospects of surplus crop production and much lower crop prices going into 2014, while not yet in hand, are very much on the horizon.
- We are entering the most weather-sensitive time of year for corn and soybean yields. Conditions over the next two months will go a long way to determining the harvest outcome.
- If these crop projections are realized in the wake of rebounding harvest results in South America, then, barring serious production shortfalls in other major producing areas of the world, the environment would be favorable for broiler and hog producers to move to an expansionary posture. Based on what we know now, we expect a 2.9% expansion for broilers and 3.1% expansion for hogs in 2014. The decision to expand would likely come at the end of the summer when the crops are in hand. Given the lag time between the decision to expand and cycle times (7 months for broilers, 12 months for hogs, 2 years for cattle), an actual increase would be weighted toward 2H14.
- Mark McMinimy's projected declines in 2013 crop corn and soybean meal prices of the order of roughly one-third each (expecting corn price of \$4.40/bushel to \$5.20/bushel, down from \$6.75 to \$7.15 in 2012) would augur for a rising ratio of live animal prices to feed costs, which should be a green light for expanding output.
- Poor forage conditions across much of the Plains appears to be derailing the possibility that U.S. ranchers will retain more
 female cattle for calf-bearing this year that would lead to an expansion in the national herd. Such an expansion now seems
 unlikely to occur before 2015, even if feed and forage conditions continue to improve. In addition to lower corn and soybean
 prices, cattle producers also need to see adequate forage (an important component of feed for cattle) to expand cattle
 herd sizes.
- The July WASDE report made relatively few changes that were incremental in scope in projections of crop production and prices compared with a month ago. That is not surprising since the weather has been relatively benign.

Potential Stock Moving Catalysts. 1) 2Q13 earnings, 8/6/13; 2) August WASDE report, 8/12/13; 3) new product launches; 4) expansion into adjacent categories; 5) U.S. drought subsides; and 6) strong flea and tick season.



SECTOR: SPECIALTY PHARMACEUTICALS July 12, 2013

ANALYST CERTIFICATION

By issuing this research report, each Guggenheim Securities, LLC ("Guggenheim Securities") research analyst whose name appears in this report hereby certifies that (i) all of the views expressed in this report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst.

IMPORTANT DISCLOSURES

The research analyst(s) and research associate(s) have received compensation based upon various factors, including quality of research, investor client feedback, and Guggenheim Securities, LLC's overall revenues, which includes investment banking revenues.


Guggenheim Securities, LLC managed or co-managed a public offering of securities for Zoetis Inc. during the past 12 months.

Zoetis Inc. is or was during the 12-month period preceding the date of the distribution of this report a client of Guggenheim Securities. Guggenheim Securities, LLC Provided Zoetis Inc.investment banking services.

Guggenheim Securities, LLC or its affiliates expect(s) to receive or intend(s) to seek compensation for investment banking services from Zoetis Inc. in the next 3 months.

For the first quarter 2013, this analyst did not timely, within 30 days of the end of the quarter, provide certifications to the Firm representing that, in connection with public appearances, the views expressed were consistent with his personal views and that no part of his/her compensation was related to his/her recommendation. The certifications were provided shortly thereafter.

Please refer to this website for company-specific disclosures referenced in this report: https://guggenheimsecurities.bluematrix.com/sellside/Disclosures.action. Disclosure information is also available from Compliance, 330 Madison Avenue, New York, NY 10017.



RATING DEFINITIONS

BUY (B) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

NEUTRAL (N) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 15% within a 12-month period.

SELL (S) - Describes stocks that we expect to provide a total negative return (price appreciation plus yield) of 15% or more within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Guggenheim Securities, LLC policies.

CS - Coverage Suspended. Guggenheim Securities, LLC has suspended coverage of this company.

NC - Not covered. Guggenheim Securities, LLC does not cover this company.

Restricted - Describes issuers where, in conjunction with Guggenheim Securities, LLC engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

Monitor - Describes stocks whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.



SECTOR: SPECIALTY PHARMACEUTICALS

July 12, 2013

Guggenheim Securities, LLC methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

			IB Serv./ Past 12Mos.	
Rating Category	Count	Percent	Count	Percent
Buy	84	54.90%	5	5.95%
Neutral	69	45.10%	5	7.25%
Sell	0	0.00%	0	0.00%

OTHER DISCLOSURES

This research is for our clients and prospective clients only. Other than disclosures relating to Guggenheim Securities and its affiliates, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the research analyst's judgment. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business, and one or more of its affiliates conduct an investment management business. Guggenheim Securities is a member of SIPC (http://www.sipc.org). Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our employees trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim Securities or certain of its affiliates conducts an investment management business, trades for its own account, and conducts an investment business, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim Securities' research, and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

TACTICAL TRADING IDEA DISCLAIMER

Guggenheim Securities, LLC produces "Tactical Trade Ideas" that identify short-term, catalyst-driven trading opportunities impacting companies within the Firm's coverage universe. Tactical Trade Ideas may exist on companies in this report and may be contrary to the analyst's published rating.

Copyright © 2013 by Guggenheim Securities, LLC, ("Guggenheim") a FINRA registered broker-dealer. All rights reserved. The contents of this report are based upon information or are obtained from sources that Guggenheim generally considers reliable, but Guggenheim makes no representations or warranties with respect to their accuracy, completeness, timeliness, suitability or otherwise, and assumes no responsibility to update them for subsequent events or knowledge. Guggenheim is not responsible for your use of this information.

Contact Information

NEW YORK SALES & TRADING DESK

212 292 4700

EQUITY TRADING DESK

212 292 4701

MEDIA INQUIRIES

312 977 4029

FMAII

general@guggenheimcm.com

Locations

NEW YORK

330 Madison Avenue New York, NY 10017

CHICAGO

222 West Adams Street

Chicago, IL 60606

BOSTON

500 Boylston St, 13th Floor Boston, MA 02116 **LOS ANGELES**

15821 Ventura Blvd Encino, CA 91436 999 Corporate Drive

Ladera Ranch, CA 92694

DALLAS

1717 McKinney Avenue

Suite 870 Dallas, TX 75202 NASHVILLE

104 Woodmont Blvd

Suite 203

Nashville, TN 37205

HERNANDO

1288 Byhalia Road

Suite 2

Hernando, MS 38632

Guggenheim Equity Research

AUTOMOTIVE

Matthew Stover, Analyst

matthew.stover@guggenheimpartners.com 617 859 4605

Brendon Mason, Associate

brendon.mason@guggenheimpartners.com 617 859 4624

ENERGY: EXPLORATION & PRODUCTION

Rob Cordray, Analyst

robert.cordray @ guggenheim partners.com

972 638 5509

Steven Hader, Associate

steven.hader@guggenheimpartners.com

972 638 5507

ENERGY: OIL SERVICES & EQUIPMENT

Darren Gacicia, Analyst

darren.gacicia@guggenheimpartners.com

212 293 3054

Michael LaMotte, Analyst

michael.lamotte@guggenheimpartners.com

214 613 6700

FINANCIAL INDUSTRY GROUP Rahul Agarwal, Associate

rahul.agarwal@guggenheimpartners.com 615 208 1221

Taylor Brodarick, Analyst

taylor.brodarick@guggenheimpartners.com 615 208 1222

David Darst, Analyst

david.darst@guggenheimpartners.com

615 208 1224

Marty Mosby, Analyst

marty.mosby@guggenheimpartners.com 662 469 9595

Mason Mosby, Associate

mason.mosby @ guggenheimpartners.com

662 469 9595

HEALTHCARE: BIOTECH Bret Holley, Analyst

bret.holley@guggenheimpartners.com 212 293 2820

HEALTHCARE: PHARMACEUTICALS Louise Chen, Analyst

louise.chen@guggenheimpartners.com 212 381 4195

Swati Kumar, Associate

swati.kumar@guggenheimpartners.com 212 918 8754

RETAIL & CONSUMER

Steven Forbes, Associate

steven.forbes@guggenheimpartners.com 212 381 4188

John Heinbockel, Analyst

john.heinbockel@guggenheimpartners.com 212 381 4135

U.S. CABLE

Sabina Nyckowski, Analyst

sabina.nyckowski@guggenheimpartners.com 212 292 4778